Oat

Oat (Avena sativa L.): A Comprehensive Reference

1. Identity, Botanical Classification, and Natural Source

Botanical name: Avena sativa L. Family: Poaceae (grass family). Common names: Oat, common oat; Avena (Spanish), Hafer (German).

Avena sativa is a member of the grass (Poaceae) family and an annual with tall, hollow stems that can grow up to 1.2 meters (approximately four feet) in height. The stems produce flat, bladelike leaves and loosely branched inflorescences, or panicles, that produce golden seeds. Its characteristic seeds hang down from thin but tough stems that emerge from the top of the plant. These plants are found most commonly in field margins of arable crops and in hedgerows and meadows.

Oats refers specifically to the species Avena sativa, which is cultivated oats, while Avena fatua is the true common wild oat species. Oats have been cultivated for hundreds of years and there are now about 25 commercial varieties. Oats are the sixth most significant cereal crop in the world, with production exceeding 24 million tons annually, and Avena sativa is the most important crop.

The genus name Avena derives from the Latin word for grain. "Avena" comes from Latin, meaning "grain," rooted in the ancient agricultural practices of Europe, where various grains were cultivated for sustenance. The Latin word "avena" specifically referred to oats, highlighting their significance in the diet of early civilizations. "Sativa" means "cultivated," indicating that oats have been selectively grown and bred by humans for thousands of years, enhancing their qualities for consumption and agricultural use.

Parts Used and Common Preparations

The parts of the plant used medicinally are the grains, immature seeds (milky oats), and leaf and stem (oatstraw). These seeds, or groats, are the main part of the plant used commercially, though the immature seeds and fresh or dried aerial parts are used in medicinal preparations.

• Mature grain (groats and processed products): Rolled oats (oatmeal), steel-cut oats, oat flour, oat bran, and oat-based beverages. The grain is the primary commercial and dietary form.
• Oat bran: The outer layer of the oat grain, concentrated in beta-glucan fiber; used as a food ingredient and in supplemental fiber products.
• Colloidal oatmeal: Finely ground oat flour dispersed in water; used in topical dermatological preparations including baths, creams, and lotions.
• Fresh milky oat tops (Avenae herba recens): Fresh milky oat tops are the premier medicinal preparation for nervous system restoration in Western clinical herbalism. This is the form that exudes a white, milky latex when the unripe grain is squeezed. The fresh material must be tinctured immediately (within hours) in high-proof ethanol, as drying destroys the milky latex and substantially diminishes the nervine trophorestorative activity.
• Dried oat straw (Avenae stramentum): The dried aerial parts (straw) of the mature plant are the form most commonly available commercially and recognized in European pharmacopeias, used as a nourishing, mineral-rich infusion.
• Oat oil: Oats, apart from maize, comprise a high oil content used for a wide range of beneficial purposes.

2. Traditional and Historical Use

Prehistory and Ancient Cultivation

Excavations from 32,600 years ago in Italy revealed thermal pre-treatment and grinding of oat seeds. However, the cultivation of oats as a crop developed much later than that of wheat. It has been suggested that the common oat (Avena sativa) spread as a weed impurity of wheat and barley seeds between four and five thousand years ago, in the Bronze Age, from the Near East to Central and North Europe. The domestication of Avena sativa occurred later than wheat and barley, initially occurring as a weed within wheat and barley fields before being cultivated in its own right approximately 3,000–4,000 years ago. The oldest known cultivated oats were found in caves in Switzerland and are believed to hail from the Bronze Age.

Ancient Greece and Rome

The ancient Greeks were the first people known to have made a recognisable porridge (cereal) from oats. Traditionally, oats have been used in various cultures for their calming effects, with ancient civilizations like the Greeks and Romans incorporating them into remedies for stress and digestive issues.

European Herbal Tradition

As the use of oat spread in traditional Western medicinal practices, both dried and fresh oats were used for a wide variety of conditions, including anxiety, stress, skin diseases, bladder disorders, blood vessel and lung ailments, and gastrointestinal disorders. German physician and botanist Adam Lonicer (1528–1586) wrote in his 1557 herbal treatise Kräuter-Buch that oats were not only nutritious but also useful in poultices, to treat fistulas.

Traditional European herbalism extensively documented the use of oat straw and milky oat fruit for its nourishing and restorative properties. In these early times, oats were esteemed not only as a staple food but also as a vital component of natural healing, used to bolster strength and vitality among people recovering from illness.

In the modern Western herbal tradition, oats are considered a nervine, relaxant, antispasmodic, antidepressant, demulcent, and restorative. In the US Eclectic medical tradition of the 19th and early 20th centuries, oats were used, in the words of physician Finley Ellingwood, MD, as a "remedy of great utility in loss of nerve power and in muscular feebleness from lack of nerve force."

Ayurvedic and Traditional Asian Use

A decoction of common oats has been used in Ayurvedic medicine to treat opium addiction. Traditional Chinese Medicine embraced oats for their warming and strengthening qualities, particularly considered beneficial for the spleen and stomach.

Official Traditional Recognitions

The German Commission E monographs list oat straw (stems and leaves) as an approved herb for external application in the case of "inflammatory and seborrheic skin disease, especially those with itching." The Commission E also records uses of oat herb "for acute and chronic anxiety, stress and excitation, neurasthenic and pseudoneurasthenic syndromes, skin diseases, connective tissue deficiencies, weakness of the bladder, and as a tonic and roborant."

The European Medicines Agency's (EMA) Committee on Herbal Medicinal Products (HMPC) has monographs for "Avenae herbae" (oat herb/oat straw) and "Avenae fructus" (oat grain). For oat grain, the HMPC concluded that it is a "traditional herbal medicinal product for the symptomatic treatment of minor inflammations of the skin (such as sunburn)" and "an aid in healing of minor wounds," while oat herb preparations are a "traditional herbal medicinal product for relief of mild symptoms of mental stress and to aid sleep."

3. Key Constituents and Active Compounds

Avena sativa has an advantage because it contains proteins, avenanthramides, lipids, beta-glucan, alkaloids, flavonoids, triterpenoid saponins, and sterols. The bioactive molecules of Avena sativa include avenanthramides, tocols, β-glucan, lignans, anthocyanidins, arabinoxylans, and other polysaccharides.

Beta-Glucan

In the Western diet, oats are an important source of soluble fiber, the main component of which is (1→3)(1→4)-β-D-glucan, commonly known as β-glucan. Found mainly in the endosperm cell wall of oats, β-glucan is thought to reduce total serum and low-density lipoprotein cholesterol by forming a viscous mass in the small intestine, thus limiting intestinal absorption of dietary cholesterol as well as the re-absorption of bile acids. β-glucan is a linear polysaccharide composed of D-glucose monomers joined by (1→4)-glycosidic bonds (~70%) with an occasional (1→3)-glycosidic bonds (~30%). Its molecular weight and the viscosity it generates in solution are considered critical determinants of its physiological potency.

Avenanthramides

Avenanthramides (Avns), the polyphenolic molecules identified solely in oats, exhibit anti-inflammatory activity mainly by inducing nuclear factor-kappaB (NF-κB) inactivation. Avns downregulated the expression of IκB kinase beta (IKKβ) and attenuated the expression of tumor necrosis factor alpha (TNFα) and interleukin 1β (IL-1β) at the transcriptional level under oxidative stress conditions. Avenanthramides are characteristic constituents of oat seeds. Avenanthramides are phenolic compounds present in oats at approximately 300 parts per million (ppm) and exhibit antioxidant activity in various cell types.

Tocols (Vitamin E Forms)

Oats have antioxidants such as vitamin E, flavonoids, and phenolic acid compounds such as avenanthramides. The tocol fraction of oats includes both tocopherols and tocotrienols, which contribute to the antioxidant capacity of the grain and protect lipid fractions from oxidative degradation.

Proteins (Avenins) and Other Constituents

The water-insoluble storage proteins of oat are called avenins. Avenins are present at a lower concentration (10%–15% of total protein content) in oat as compared to gluten in wheat (80%–85%).

Colloidal oatmeal contains starch (65–85%), proteins (15–20%), lipids (3–11%), fiber (5%), and beta-glucans (5%). The lipid content is much higher than in other cereal grains, with unsaturated triglycerides rich in unsaturated fatty acids being the most abundant lipids.

4. Mechanisms of Action

Cholesterol and Bile Acid Modulation

The cholesterol-lowering effects of oat consumption are proposed to be mediated by the gel-forming properties of oat β-glucan, which modulates host bile acid and cholesterol metabolism and potentially removes intestinal cholesterol for excretion. Oat β-glucan has been shown to modulate the gut microbiota, particularly those bacterial species that influence host bile acid metabolism and production of short chain fatty acids, factors which are regulators of host cholesterol homeostasis. Given a significant role for the gut microbiota in cholesterol metabolism, it is likely that the effects of oat β-glucan on the host are multifaceted and involve regulation of microbe-host interactions at the gut interface.

Glycemic Modulation

Viscosity interferes with the peristaltic mixing process in the small intestine to impede digestion and absorption of nutrients, which precipitates satiety signals. From measurements of the physicochemical and rheological properties of β-glucan, it appears that viscosity plays a key role in modulating satiety.

Prebiotic and Short-Chain Fatty Acid Production

Oat beta-glucan can be fermented by the intestinal microbiome, which produces short-chain fatty acids (SCFAs) and affects gut microbiome composition, acting as a prebiotic. Beta-glucan also has significant effects on bile acid metabolism and composition. In the colon, dietary fiber may be fermented by gut microbes to short-chain fatty acids, namely butyrate, propionate, and acetate, which activate the enteroendocrine cells of the gut to secrete a host of metabolically active peptides involved in food intake, lipid storage, and energy homeostasis.

Anti-inflammatory Activity (Topical)

Studies have demonstrated that avenanthramides can inhibit the activity of nuclear factor kappaB and the release of proinflammatory cytokines and histamine, well known key mechanisms in the pathophysiology of inflammatory dermatoses. Proteins in colloidal oatmeal are very effective pH buffers that can counteract elevated skin pH and improve appropriate stratum corneum integrity, barrier function, and antimicrobial activity.

5. Scientific Evidence by Area of Use

5.1 Cardiovascular Health: LDL Cholesterol Reduction

This is the best-evidenced area of oat research, supported by multiple regulatory health claim approvals.

A significant body of evidence demonstrates that consumption of oat products is linked to a reduction in serum LDL cholesterol, a risk factor for the development of cardiovascular disease (CVD). It is well established that consuming oat β-glucan (OBG) lowers LDL cholesterol, and regulatory agencies in the United States, Canada, and Europe allow a claim that including a daily amount of 3 g OBG in food products can help to reduce blood cholesterol.

A meta-analysis was performed on 28 RCTs comparing ≥3 g OBG/day with an appropriate control. A 2022 systematic review and meta-analysis (Yu et al., Nutrients) further examined this question: the review probed the effect of oat beta-glucan consumption on serum lipid profiles (total cholesterol, total triglyceride, HDL-cholesterol, and LDL-cholesterol); literature was obtained from PubMed, Scopus, Cochrane Library, Web of Science, and Embase from inception to 28 February 2022, and thirteen trials with 927 participants were included.

Specific trial data: The daily consumption in reviewed trials ranged between 1.6 and 6 g of oat beta-glucans per day and interventions ran from three to eight weeks. The BELT study, a 2020 placebo-controlled trial by Cicero et al. of 83 Italian participants with mild hypercholesterolemia over eight weeks, found that 3 g per day of oat beta-glucans reduced total cholesterol by 8.9% after eight weeks and non-HDLs were reduced by 12.1%.

It is believed that the cholesterol-lowering effect of OBG depends on its viscosity in the small intestine, which, in turn, is affected by the molecular weight and amount of β-glucan in solution.

Additionally, a randomized controlled trial in 60 hypercholesterolemic patients assessed vascular function: sixty hypercholesterolemic patients were randomly divided to receive an experimental bread rich in beta-glucan from oat bran (intervention) or bread rich in wheat fiber (control) for four weeks, with serum nitric oxide concentration and flow-mediated dilation (FMD) determined before and after. After intervention, serum nitric oxide concentration increased significantly in the intervention group (P = 0.017), but no change was observed in the control group.

Evidence strength: Strong. Multiple RCTs and meta-analyses support this effect. The 3 g/day OBG threshold is recognized by the FDA, Health Canada, and EFSA as the basis for approved health claims.

5.2 Glycemic Control and Diabetes

The efficacy of oat beta-glucan (OBG), a viscous soluble fibre, on postprandial glycemic outcomes may depend on the nature of the control and the dose and molecular weight utilized. A large systematic review and meta-analysis (Zurbau et al., 2021) addressed this directly: to determine the effect of oat β-glucan on acute glucose and insulin responses, MEDLINE, EMBASE, and Cochrane databases were searched through October 27, 2020, for acute, crossover, controlled feeding trials investigating the effect of adding OBG (concentrate or oat-bran) to carbohydrate-containing test-meals. The primary outcome was glucose incremental area-under-the-curve (iAUC). This analysis included 103 trial comparisons (N = 538).

Current evidence indicates that the addition of oat beta-glucan to carbohydrate-containing meals reduces the postprandial glycemic response. However, the magnitude of the reduction depends on the dose and the molecular weight of the oat beta-glucan.

For longer-term glycemic outcomes in type 2 diabetes (T2DM): Many individual studies on oat β-glucan confirmed its functionality in improving T2DM, but disagreements were identified among results. A meta-analysis collected relevant articles from four electronic databases (PubMed, Cochrane Library, Scopus, and Web of Science), and four articles dealing with 350 T2DM patients combined met the inclusion criteria. However, for fasting glycemic control specifically, results have been mixed: evidence from observational studies has supported the beneficial effects of beta-glucan intake on glycemic control, but intervention studies in hypercholesterolemic individuals have generated mixed results. Twelve trials with a total of 603 subjects were included in one meta-analysis, and beta-glucan consumption did not significantly affect measures of glycemic control for fasting glucose or fasting insulin concentrations.

Evidence strength: Moderate to strong for acute postprandial blood glucose reduction; mixed for fasting glucose and long-term HbA1c outcomes.

5.3 Gut Health, Microbiome Modulation, and Satiety

Oat β-glucan supplementation for 5 weeks has been shown to promote the proliferation of bacteria such as Bifidobacterium species in healthy humans. These bacteria are associated with a beneficial effect on the host through their potential involvement in diabetes-related inflammation and the development of obesity. A clinical trial evaluating oat beta-glucan-based prebiotic blended formulas in Chinese adults found: both formulas improved defecation frequency, stool quality, defecation symptoms, defecation satisfaction, and digestive health, compared with baseline (P < 0.05). Both formulas led to increased quantities of Bifidobacterium and Akkermansia bacteria, compared to control, on day 14.

However, the evidence base for prebiotic effects remains preliminary: in vitro studies provide the majority of the data to support the prebiotic potential of oat β-glucan, but more evidence is needed before a prebiotic effect may be definitively attributed to oat β-glucan. Most studies evaluated the effect of β-glucans on the growth of Lactobacillus or Bifidobacterium species in pure cultures, the composition of human fecal microbiota in bioreactors, or the cecal microbiota in rats. Few studies were performed in humans, and most did not analyze the whole microbiota.

On satiety: oat β-glucan has been shown to promote satiety, possibly contributing to weight control. β-glucan has shown physiological benefits including weight management via increasing satiety. The results regarding the effect of β-glucans on satiety-regulating hormones are contradictory, and further studies are needed to reach a consensus.

Evidence strength: Moderate for bowel function improvements; preliminary to moderate for prebiotic and satiety effects; further high-quality human trials are needed.

5.4 Blood Pressure

A randomized controlled trial in adults with hypertension demonstrated a reduction in blood pressure in participants following a DASH diet with oat bran supplementation. The participants were also able to reduce hypertension medications and experienced changes in the gut microbiota, including increased abundance of Bifidobacterium and Spirillum populations.

Evidence strength: Preliminary; limited number of independent trials specifically targeting blood pressure as a primary endpoint; larger RCTs are needed.

5.5 Skin Health: Atopic Dermatitis, Eczema, and Pruritus

Colloidal oatmeal (finely milled Avena sativa) has a long-established use in dermatology. Colloidal oatmeal has a long history of beneficial use in dermatology. It is a natural product that has an excellent safety record and has demonstrated efficacy for the treatment of atopic dermatitis, psoriasis, drug-induced rash, and other conditions. Specifically, colloidal oatmeal gained FDA approval as a skin protectant in 2003, solidifying its role in managing conditions such as atopic dermatitis, xerosis, and pruritus.

Phenolic avenanthramides, though a minor component of colloidal oatmeal, are responsible for the anti-inflammatory properties of colloidal oatmeal use. They are thought to inhibit tumor necrosis factor-alpha induced NF-κB activity and decrease the release of interleukin-8, an inflammatory cytokine involved in neutrophil chemotaxis. Furthermore, topical application of avenanthramides reduces inflammation and scratching in murine models.

Sur and colleagues found that avenanthramides at concentrations as low as 1 part per billion diminished phosphorylation of the p65 subunit of NF-kappaB. Further, cells treated with avenanthramides showed a significant inhibition of TNF-alpha and reduction of interleukin-8 (IL-8) release. Moreover, topical application of 1–3 ppm avenanthramides allayed inflammation in murine models of contact hypersensitivity and neurogenic inflammation and reduced pruritogen-induced scratching in a murine itch model.

A clinical study in mild-to-moderate atopic dermatitis: a clinical study evaluated tolerance and efficacy of a recovering cream composed of 1% colloidal prebiotic oatmeal, lipid technology, and beta glucan active, applied on 30 Brazilian multi-ethnic mild to moderate AD patients for 21 days, with efficacy evaluated by SCORAD, POEM, instrumental measurements, and patient self-assessment at baseline and after 5, 7, 14, and 21 days. SCORAD reduced in 100% of patients since day 5 (p < 0.001), with visible reduction in AD extent and severity.

The level of anti-inflammatory effect of avenanthramides is reported to be similar to that of topical 1% hydrocortisone. With its high concentration of starches and beta-glucan, colloidal oatmeal is water-attracting and helps the skin retain water.

Evidence strength: Strong for topical applications in atopic dermatitis, xerosis, and pruritus. The FDA recognizes colloidal oatmeal as an over-the-counter Category I skin protectant. The molecular mechanisms (NF-κB inhibition, cytokine reduction) are well characterized in vitro; clinical evidence supports improvement in validated eczema scores.

5.6 Nervous System (Nervine/Adaptogenic): Traditional Claims, Limited Clinical Evidence

Extracts of milky oat have been investigated based on their traditional use as a nervine. A primary modern use for milky oat tops is to support the nervous system. In traditional and contemporary herbalism, milky oats are often referred to as a "nervine trophorestorative," suggesting they help nourish and restore a depleted nervous system.

In October 1987, the German Commission E stated that oat straw could be used as a nervine herb. The German government went on to commission oat straw as an effective remedy for anxiety and stress. The EMA's HMPC similarly classifies oat herb preparations as a traditional herbal medicinal product for relief of mild symptoms of mental stress and to aid sleep, noting this as traditional use rather than evidence-based use in the European Union regulatory sense.

Evidence strength: Weak to preliminary for clinical nervous system effects. The regulatory categorization in Europe is as "traditional use," indicating historical evidence rather than robust RCT data. No large, well-designed RCTs have specifically confirmed clinical efficacy of milky oat or oat straw preparations for anxiety or nervous exhaustion in humans.

6. Body Systems Associated with Oat

• Cardiovascular system: LDL cholesterol reduction, vascular endothelial function, blood pressure modulation via beta-glucan.
• Digestive / gastrointestinal system: Bowel regularity, gut microbiota modulation, short-chain fatty acid production, satiety.
• Endocrine / metabolic system: Postprandial glycemic regulation, insulin sensitivity, weight management.
• Integumentary (skin) system: Anti-inflammatory, barrier-restoring, antipruritic, and moisturizing properties of colloidal oatmeal in atopic dermatitis, psoriasis, and xerosis.
• Nervous system: Traditionally used as a nervine and trophorestorative (evidence from traditional use; clinical evidence limited).
• Immune system: Oat extract has application in pharmacological activities including anti-inflammatory, antioxidant, and immunomodulatory activities.

7. Dosage Forms and Doses Reported in Studies

The following dosages are drawn directly from the cited research and regulatory sources, and are not recommendations:

• Beta-glucan for cholesterol reduction (oral): The recommended intake of beta-glucan for reduction of cholesterol is 3 g/day, an amount found in approximately 90 g of oats. The objective of the major meta-analysis (Whitehead et al., 2014) was to quantify the effect of ≥3 g OBG/day on serum cholesterol concentrations in humans.
• Range across cholesterol trials: The daily consumption ranged between 1.6 and 6 g of oat beta-glucans per day and the interventions ran from three to eight weeks.
• Specific BELT study dose: In the BELT study, 3 g per day of oat beta-glucans was administered over eight weeks.
• Oat beta-glucan bread (vascular function trial): Sixty hypercholesterolemic patients received an experimental bread rich in beta-glucan from oat bran for four weeks.
• Topical colloidal oatmeal (atopic dermatitis): A clinical study used a recovering cream composed of 1% colloidal prebiotic oatmeal applied over 21 days in mild to moderate AD patients.
• Topical avenanthramide activity range: Topical application of 1–3 ppm avenanthramides has allayed inflammation in murine models of contact hypersensitivity.

8. Safety Considerations and Notable Interactions

General Safety Status

The US Food and Drug Administration (FDA) has granted oats Generally Recognized as Safe (GRAS) status when used as food. Health effects of oat consumption are reflected in EFSA- and FDA-approved health claims.

Oats and Celiac Disease

The relationship between oats and celiac disease is complex and the subject of ongoing scientific debate. The water-insoluble storage proteins of oat are called avenins (not gluten). Avenins are present at a lower concentration (10%–15% of total protein content) in oat as compared to gluten in wheat (80%–85%). The avenins in the genus Avena are free of the known celiac disease immunogenic epitopes from wheat, barley, and rye. T cells that recognize avenin-specific epitopes have been found very rarely in CD patients. CD patients that consume oats daily do not show significantly increased levels of intraepithelial lymphocyte (EIL) cells. The safety and the positive health effects of the long-term inclusion of oats in the gluten-free diet have been confirmed in long-term studies.

Despite this, contamination is a documented concern: since 2009 (EC 41/2009) and 2013 (FDA), oat products may be sold as gluten-free in several countries provided a gluten contamination level is below 20 ppm. The collective uncertainty of these findings regarding the true clinical safety of oats in celiac disease has translated into different feeding recommendations; while Australia and New Zealand mandate the exclusion of oats from the gluten-free diet, most countries do not. Introduction of oats in the gluten-free diet of celiac patients is advised after the recovery of the intestine.

Drug Interactions

Oat bran may decrease absorption of medications. This is consistent with the general mechanism by which viscous soluble fibers slow gastric emptying and reduce intestinal absorption of macronutrients and potentially co-administered drugs. Oats have been specifically noted as potentially reducing absorption of some co-administered drugs due to this fiber matrix effect.

Topical Safety

Although more than 8 million oat-based cosmetics are sold yearly, there are very few reports of allergic contact dermatitis or contact urticaria. Colloidal oatmeal has a long history of beneficial use in dermatology. It is a natural product that has an excellent safety record.

Pregnancy and Breastfeeding

Oats and oat straw are considered safe for use during pregnancy and breastfeeding.

Evidence Limitations Noted Across Research

Across the body of research, several limitations recur. Study heterogeneity in beta-glucan dose, molecular weight, food matrix, and control conditions makes direct comparison difficult. Current evidence indicates that OBG reduces the postprandial glycemic response, but the magnitude of the reduction depends on the dose and the molecular weight of the oat beta-glucan. For gut microbiome effects, few studies were performed in humans and most did not analyze the whole microbiota, but only some specific bacterial populations. For nervous system claims, clinical human evidence remains sparse and largely confined to traditional use designations rather than RCT-level proof.

References

• Rasane P, et al. "Multiple Antioxidative and Bioactive Molecules of Oats (Avena sativa L.) in Human Health." Antioxidants (Basel). 2021 Sep 13;10(9):1428. PMC8471765.
• Joyce SA, Kamil A, Fleige L, Gahan CGM. "The Cholesterol-Lowering Effect of Oats and Oat Beta Glucan: Modes of Action and Potential Role of Bile Acids and the Microbiome." Front Nutr. 2019 Nov 27;6:171. PMC6892284.
• Whitehead A, Beck EJ, Tosh S, Wolever TM. "Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials." Am J Clin Nutr. 2014;100(6):1413–1421. PubMed 25411276.
• Yu J, Xia J, Yang C, et al. "Effects of Oat Beta-Glucan Intake on Lipid Profiles in Hypercholesterolemic Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Nutrients. 2022 May 13;14(10):2043. PMC9147392.
• Zurbau A, Noronha JC, Khan TA, Sievenpiper JL, Wolever TMS. "The effect of oat β-glucan on postprandial blood glucose and insulin responses: a systematic review and meta-analysis." Eur J Clin Nutr. 2021. PMC8563417.
• Tiwari U, Cummins E. "Meta-analysis of the effect of β-glucan intake on glycemic control." Nutrition. 2011. PubMed 26001090.
• He LX, et al. "Effect of Oat β-Glucan Intake on Glycaemic Control and Insulin Sensitivity of Diabetic Patients: A Meta-Analysis of Randomized Controlled Trials." PMC4728652.
• Rebello CJ, O'Neil CE, Greenway FL. "Dietary fiber and satiety: the effects of oats on satiety." Nutr Rev. 2016 Feb;74(2):131–47. PMC4757923.
• Damián MRS, et al. "Relationship between Oat Consumption, Gut Microbiota Modulation, and Short-Chain Fatty Acid Synthesis: An Integrative Review." PMC10459712.
• Fowler JF Jr., et al. "Mechanism of action and clinical benefits of colloidal oatmeal for dermatologic practice." J Drugs Dermatol. 2010 Sep;9(9):1116. PubMed 20865844.
• Kurtz ES, Wallo W. "Colloidal Oatmeal Formulations and the Treatment of Atopic Dermatitis." J Drugs Dermatol. 2007;6(2):167–170.
• Gilissen LJWJ, et al. "Why Oats Are Safe and Healthy for Celiac Disease Patients." Med Sci (Basel). 2016;4(4):21. PMC5635790.
• Tye-Din JA, et al. "Preparation and Characterization of Avenin-Enriched Oat Protein for Feeding Trials in Celiac Disease." Front Nutr. 2019. PMC6803533.
• Queenan KM, et al. "Concentrated oat beta-glucan, a fermentable fiber, lowers serum cholesterol in hypercholesterolemic adults in a randomized controlled trial." Nutr J. 2007;6:6. PMC1847683.
• Shavakhi A, et al. "The Effects of Beta-Glucan Rich Oat Bread on Serum Nitric Oxide and Vascular Endothelial Function in Patients with Hypercholesterolemia." PMC4082950.
• Herb Profile: Oat. HerbalGram Issue 135. American Botanical Council.
• Whitehead A, et al. "Cholesterol-lowering effects of oat beta-glucan: a meta-analysis of randomized controlled trials." Database of Abstracts of Reviews of Effects (DARE). NCBI Bookshelf NBK292164.
• Strasser M, et al. "Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progression." PMC10844974.
• Noronha JC, et al. "The importance of molecular weight in determining the minimum dose of oat β-glucan required to reduce the glycaemic response." PMC10017511.
• Mahmoud NE, et al. "Boosting vegetation, biochemical constituents, grain yield and anti-cancer performance of cultivated oat (Avena sativa L) in calcareous soil." BMC Plant Biol. 2022. PMC9700955.